Pharmafile Logo
Pharmafocus logo
Advanced Search

Parkinson’s disease

Showing 15 posts of 15 posts found.

Amneal and Zambon Biotech enter agreement for Parkinson’s treatment

February 28, 2024
Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement

Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …

News
170124-f-ds634-005

Experimental drug could treat dyskinesia in people with Parkinson’s

March 2, 2020
Sales and Marketing Parkinson's, Parkinson's disease, dyskinesia, spasms

Results from a new study researching treatment for dyskinesia has offered hope that it may be treatable in people with …

News
insider_interview_andrew_roach

A new weapon against Parkinson’s-related psychosis

December 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma

Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …

Feature
800px-blausen_0704_parkinsonsdisease

Scientists at King’s College London identify early signs of Parkinson’s disease

June 20, 2019
Research and Development King's College London, Kings College London, Parkinson's disease, pharma, serotonin

Scientists at King’s College London say they have identified the earliest signs of Parkinson’s disease in the brain – 15 …

News
nerves

Parkinson’s disease: A quest for steadier therapies

June 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, biotech, drugs, pharma, pharmaceutical

The worrying number of deaths associated with Nuplazid has eyes returning to the pipeline for Parkinson’s disease. Anjali Shukla, a …

Feature
asthma

Asthma drugs reduce Parkinson’s risk by 50%, decade-long study finds

September 5, 2017
Manufacturing and Production, Research and Development Parkinson's, Parkinson's disease, asthma, pharma, pharmaceuticals, salbutamol

A study from the Department of Global Public Health and Primary Care at the University of Bergen (UiB) in Norway …

News
brain-1845962_960_720

Diabetes drug holds promise to slow Parkinson’s progression

August 4, 2017
Medical Communications, Research and Development Parkinson's disease, biotech, diabetes, drugs, pharma, pharmaceutical

There are currently no treatments that are able to slow the development of Parkinson’s disease. This unmet medical need will …

News

Pfizer, IBM partner to develop monitoring system for Parkinson’s disease

April 8, 2016
Medical Communications, Research and Development Parkinson's disease, Pfizer, collaboration, ibm, research, technology

US pharma giant Pfizer (NYSE: PFE) and International Business Machines Corp (NYSE: IBM) have partnered on a research project focussed on …

News
AbbVie

NHS England approves AbbVie’s Duodopa for Parkinson’s disease

July 6, 2015
Sales and Marketing AbbVie, Duodopa, James Palmer, NHS England, PPRS, Parkinson's, Parkinson's disease, commissioning

AbbVie has been handed a boost by NHS England, who has approved the prescribing of its Parkinson’s disease treatment Duodopa …

News

UCB launches ‘Parkinson’s Well-Being Map’

April 13, 2012
Medical Communications Parkinson's disease, UCB

UCB has launched a new visual tool to help people with Parkinson’s Disease to discuss their health and symptoms with …

News
GlaxoSmithKline

GSK Parkinson’s drug shows motor skills benefits

August 16, 2011
Research and Development GSK, Impax Pharmaceuticals, Parkinson's disease, research and development news

GlaxoSmithKline’s new drug IPX066 has helped Parkinson’s disease patients retain their motor skills after their medication wore off. IPX066, which …

News

GSK Parkinson’s drug impresses at phase III

March 21, 2011
Research and Development ADVANCE-PD, GSK, GlaxoSmithKline, IPX066, Impax Pharmaceuticals, Parkinson's disease, Parkinson’s disease

GlaxoSmithKline’s advanced Parkinson’s disease drug IPX066 has impressed in a head to head trial against it nearest rival. The phase …

News

Merck Serono and Domain to co-develop Parkinson’s drugs

January 18, 2011
Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4

Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …

News

Biogen Idec buys neurodegenerative disease rights

December 21, 2010
Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

News

Trial failure for Merck Serono’s Parkinson’s candidate

November 8, 2010
Research and Development Merck Serono, Newron Pharmaceuticals, Parkinson's disease, dopamine agonists, levodopa, safinamide

Merck Serono’s new alpha-aminoamide safinamide has failed to reach its primary endpoint in a study with Parkinson’s disease patients. Merck …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024